Skip to content

Study · Randomized controlled trial · n = 19 · 1997

26 results

Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women.

Khorram O, Laughlin GA, Yen SS

The Journal of clinical endocrinology and metabolism1 May 1997Cited by 25 (Europe PMC)

PMID9141536 (opens in a new tab)DOI10.1210/jcem.82.5.3943 (opens in a new tab)PepBankPUB-09141536
Source linkPubMedAsk about this study
Jump to 26 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study26

26 results from studies that gave the peptide. 26 results from people.

  1. 01HumanRandomized controlled trialActivity measurement

    In age-advanced men and women, nightly GHRH analog induced an acute release of GH within 10 min that lasted for 2 h.

    In plain wordsIn older men and women, a nightly GHRH analog dose triggered a quick release of growth hormone within 10 minutes.

    Peptide
    Sermorelin
    Outcome
    IncreaseAcute GH release after nightly dose
    Study

    n = 19

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    10 microg/kg · subcutaneous · 16 weeksAs given in this study (human).

    Source sentences

    Summary
    Nightly GHRH analog administration at 2100 h induced, within 10 min, an acute release of GH, which lasted for 2 h.
    2 context sentences
    Summary · context
    A single blind, randomized, placebo-controlled trial of 5 months duration was conducted.
    Summary · context
    Ten women and 9 men between the ages of 55-71 yr self-injected placebo (saline) s.c. nightly for 4 weeks followed by 16 weeks of [Nle27]GHRH-(1-29)-NH2 at a dose of 10 microg/kg.
  2. 02HumanRandomized controlled trialActivity measurement

    In age-advanced men and women, the GH-releasing effect of the GHRH analog was sustained during the study.

    In plain wordsIn older men and women, the growth hormone release caused by the GHRH analog did not fade during the study.

    Peptide
    Sermorelin
    Outcome
    No significant changeSustained GH-releasing effect
    Study

    n = 19

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    10 microg/kg · subcutaneous · 16 weeksAs given in this study (human).

    Source sentences

    Summary
    The GH-releasing effect of GHRH analog was sustained during the course of the study.
    2 context sentences
    Summary · context
    A single blind, randomized, placebo-controlled trial of 5 months duration was conducted.
    Summary · context
    Ten women and 9 men between the ages of 55-71 yr self-injected placebo (saline) s.c. nightly for 4 weeks followed by 16 weeks of [Nle27]GHRH-(1-29)-NH2 at a dose of 10 microg/kg.
  3. 03HumanRandomized controlled trialActivity measurement

    In age-advanced men and women, the GHRH analog increased serum IGF-I within 2 weeks; it stayed elevated for 12 weeks.

    In plain wordsIn older men and women, the GHRH analog raised blood IGF-I within 2 weeks.

    Peptide
    Sermorelin
    Outcome
    IncreaseSerum IGF-I
    Study

    n = 19

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    10 microg/kg · subcutaneous · 16 weeksAs given in this study (human).

    Source sentences

    Summary
    This was accompanied, within 2 weeks, by increased serum levels of IGF-I (P < 0.05)
    2 context sentences
    Summary · context
    A single blind, randomized, placebo-controlled trial of 5 months duration was conducted.
    Summary · context
    Ten women and 9 men between the ages of 55-71 yr self-injected placebo (saline) s.c. nightly for 4 weeks followed by 16 weeks of [Nle27]GHRH-(1-29)-NH2 at a dose of 10 microg/kg.
  4. 04HumanRandomized controlled trialActivity measurement

    In age-advanced men and women, the GHRH analog increased serum IGFBP-3 within 2 weeks.

    In plain wordsIn older men and women, the GHRH analog raised blood IGFBP-3, an IGF-I carrier protein, within 2 weeks.

    Peptide
    Sermorelin
    Outcome
    IncreaseSerum IGFBP-3
    Study

    n = 19

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    10 microg/kg · subcutaneous · 16 weeksAs given in this study (human).

    Source sentences

    Summary
    This was accompanied, within 2 weeks, by increased serum levels of IGF-I (P < 0.05) and IGFBP-3 (P < 0.001), but not IGFBP-1, which remained elevated for 12 weeks, returning toward baseline by 16 weeks in both genders.
    2 context sentences
    Summary · context
    A single blind, randomized, placebo-controlled trial of 5 months duration was conducted.
    Summary · context
    Ten women and 9 men between the ages of 55-71 yr self-injected placebo (saline) s.c. nightly for 4 weeks followed by 16 weeks of [Nle27]GHRH-(1-29)-NH2 at a dose of 10 microg/kg.
  5. 05HumanRandomized controlled trialActivity measurement

    In age-advanced men and women, the GHRH analog did not increase serum IGFBP-1.

    In plain wordsIn older men and women, the GHRH analog did not raise blood IGFBP-1.

    Peptide
    Sermorelin
    Outcome
    No significant changeSerum IGFBP-1
    Study

    n = 19

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    10 microg/kg · subcutaneous · 16 weeksAs given in this study (human).

    Source sentences

    Summary
    This was accompanied, within 2 weeks, by increased serum levels of IGF-I (P < 0.05) and IGFBP-3 (P < 0.001), but not IGFBP-1, which remained elevated for 12 weeks, returning toward baseline by 16 weeks in both genders.
    2 context sentences
    Summary · context
    A single blind, randomized, placebo-controlled trial of 5 months duration was conducted.
    Summary · context
    Ten women and 9 men between the ages of 55-71 yr self-injected placebo (saline) s.c. nightly for 4 weeks followed by 16 weeks of [Nle27]GHRH-(1-29)-NH2 at a dose of 10 microg/kg.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In age-advanced men and women, GHRH analog treatment did not affect blood pressure.

    In plain wordsIn older men and women, the GHRH analog did not change blood pressure.

    Peptide
    Sermorelin
    Outcome
    No significant changeBlood pressure
    Study

    n = 19

    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    10 microg/kg · subcutaneous · 16 weeksAs given in this study (human).

    Source sentences

    Summary
    Although blood pressure and body weight were unaffected
    2 context sentences
    Summary · context
    A single blind, randomized, placebo-controlled trial of 5 months duration was conducted.
    Summary · context
    Ten women and 9 men between the ages of 55-71 yr self-injected placebo (saline) s.c. nightly for 4 weeks followed by 16 weeks of [Nle27]GHRH-(1-29)-NH2 at a dose of 10 microg/kg.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In age-advanced men and women, GHRH analog treatment did not affect body weight.

    In plain wordsIn older men and women, the GHRH analog did not change body weight.

    Peptide
    Sermorelin
    Outcome
    No significant changeBody weight
    Study

    n = 19

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    10 microg/kg · subcutaneous · 16 weeksAs given in this study (human).

    Source sentences

    Summary
    Although blood pressure and body weight were unaffected
    2 context sentences
    Summary · context
    A single blind, randomized, placebo-controlled trial of 5 months duration was conducted.
    Summary · context
    Ten women and 9 men between the ages of 55-71 yr self-injected placebo (saline) s.c. nightly for 4 weeks followed by 16 weeks of [Nle27]GHRH-(1-29)-NH2 at a dose of 10 microg/kg.
  8. 08HumanRandomized controlled trialEfficacy outcome

    In age-advanced men and women, GHRH analog treatment significantly increased skin thickness in both genders.

    In plain wordsIn older men and women, the GHRH analog increased skin thickness.

    Peptide
    Sermorelin
    Outcome
    IncreaseSkin thickness
    Study

    n = 19

    Outcome group
    Skin and hair · Skin and wound
    Studied dose
    10 microg/kg · subcutaneous · 16 weeksAs given in this study (human).

    Source sentences

    Summary
    GHRH analog treatment resulted in a significant increase in skin thickness (P < 0.05) in both genders
    2 context sentences
    Summary · context
    A single blind, randomized, placebo-controlled trial of 5 months duration was conducted.
    Summary · context
    Ten women and 9 men between the ages of 55-71 yr self-injected placebo (saline) s.c. nightly for 4 weeks followed by 16 weeks of [Nle27]GHRH-(1-29)-NH2 at a dose of 10 microg/kg.
  9. 09HumanRandomized controlled trialEfficacy outcome

    In age-advanced men and women, GHRH analog treatment caused no other changes in body composition in either gender.

    In plain wordsIn older men and women, the GHRH analog caused no other changes in body composition.

    Peptide
    Sermorelin
    Outcome
    No significant changeOther body composition measures
    Study

    n = 19

    Outcome group
    Body composition · Metabolic and weight
    Studied dose
    10 microg/kg · subcutaneous · 16 weeksAs given in this study (human).

    Source sentences

    Summary
    with no other changes in body composition or bone mineral density in either gender.
    2 context sentences
    Summary · context
    A single blind, randomized, placebo-controlled trial of 5 months duration was conducted.
    Summary · context
    Ten women and 9 men between the ages of 55-71 yr self-injected placebo (saline) s.c. nightly for 4 weeks followed by 16 weeks of [Nle27]GHRH-(1-29)-NH2 at a dose of 10 microg/kg.
  10. 10HumanRandomized controlled trialEfficacy outcome

    In age-advanced men and women, GHRH analog treatment caused no change in bone mineral density in either gender.

    In plain wordsIn older men and women, the GHRH analog did not change bone mineral density.

    Peptide
    Sermorelin
    Outcome
    No significant changeBone mineral density
    Study

    n = 19

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    10 microg/kg · subcutaneous · 16 weeksAs given in this study (human).

    Source sentences

    Summary
    with no other changes in body composition or bone mineral density in either gender.
    2 context sentences
    Summary · context
    A single blind, randomized, placebo-controlled trial of 5 months duration was conducted.
    Summary · context
    Ten women and 9 men between the ages of 55-71 yr self-injected placebo (saline) s.c. nightly for 4 weeks followed by 16 weeks of [Nle27]GHRH-(1-29)-NH2 at a dose of 10 microg/kg.
  11. 11HumanRandomized controlled trialEfficacy outcome

    In age-advanced men and women, GHRH analog treatment showed a trend for positive nitrogen balance in both genders, which became significant when the data were combined.

    In plain wordsIn older men and women, the GHRH analog showed a trend toward positive nitrogen balance, significant only when men and women were combined.

    Peptide
    Sermorelin
    Outcome
    IncreaseNitrogen balance
    Study

    n = 19

    Outcome group
    Body composition · Metabolic and weight
    Studied dose
    10 microg/kg · subcutaneous · 16 weeksAs given in this study (human).

    Source sentences

    Summary
    There was a trend for a positive nitrogen balance in both genders, which became significant (P = 0.03) when the data were combined.
    2 context sentences
    Summary · context
    A single blind, randomized, placebo-controlled trial of 5 months duration was conducted.
    Summary · context
    Ten women and 9 men between the ages of 55-71 yr self-injected placebo (saline) s.c. nightly for 4 weeks followed by 16 weeks of [Nle27]GHRH-(1-29)-NH2 at a dose of 10 microg/kg.
  12. 12HumanRandomized controlled trialEfficacy outcome

    In age-advanced men and women, fasting insulin levels were unaltered by GHRH analog treatment.

    In plain wordsIn older men and women, the GHRH analog did not change fasting insulin levels.

    Peptide
    Sermorelin
    Outcome
    No significant changeFasting insulin
    Study

    n = 19

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    10 microg/kg · subcutaneous · 16 weeksAs given in this study (human).

    Source sentences

    Summary
    Fasting insulin and glucose levels were unaltered
    2 context sentences
    Summary · context
    A single blind, randomized, placebo-controlled trial of 5 months duration was conducted.
    Summary · context
    Ten women and 9 men between the ages of 55-71 yr self-injected placebo (saline) s.c. nightly for 4 weeks followed by 16 weeks of [Nle27]GHRH-(1-29)-NH2 at a dose of 10 microg/kg.
  13. 13HumanRandomized controlled trialEfficacy outcome

    In age-advanced men and women, fasting glucose levels were unaltered by GHRH analog treatment.

    In plain wordsIn older men and women, the GHRH analog did not change fasting glucose levels.

    Peptide
    Sermorelin
    Outcome
    No significant changeFasting glucose
    Study

    n = 19

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    10 microg/kg · subcutaneous · 16 weeksAs given in this study (human).

    Source sentences

    Summary
    Fasting insulin and glucose levels were unaltered
    2 context sentences
    Summary · context
    A single blind, randomized, placebo-controlled trial of 5 months duration was conducted.
    Summary · context
    Ten women and 9 men between the ages of 55-71 yr self-injected placebo (saline) s.c. nightly for 4 weeks followed by 16 weeks of [Nle27]GHRH-(1-29)-NH2 at a dose of 10 microg/kg.
  14. 14HumanRandomized controlled trialEfficacy outcome

    In age-advanced men and women, sleep quality was unaffected by GHRH analog treatment.

    In plain wordsIn older men and women, the GHRH analog did not change sleep quality.

    Peptide
    Sermorelin
    Outcome
    No significant changeSleep quality
    Study

    n = 19

    Outcome group
    Sleep · Sleep
    Studied dose
    10 microg/kg · subcutaneous · 16 weeksAs given in this study (human).

    Source sentences

    Summary
    sleep quality was unaffected in both genders.
    2 context sentences
    Summary · context
    A single blind, randomized, placebo-controlled trial of 5 months duration was conducted.
    Summary · context
    Ten women and 9 men between the ages of 55-71 yr self-injected placebo (saline) s.c. nightly for 4 weeks followed by 16 weeks of [Nle27]GHRH-(1-29)-NH2 at a dose of 10 microg/kg.
  15. 15HumanRandomized controlled trialSafety outcome

    In age-advanced men and women, the only adverse side-effect of the GHRH analog was transient hyperlipidemia, which resolved by the end of the study.

    In plain wordsIn older men and women, the only side effect of the GHRH analog was a short rise in blood fats that went away.

    Peptide
    Sermorelin
    Outcome
    IncreaseTransient hyperlipidemia
    Study

    n = 19

    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    10 microg/kg · subcutaneous · 16 weeksAs given in this study (human).

    Source sentences

    Summary
    The only adverse side-effect was transient hyperlipidemia, which resolved by the end of the study.
    2 context sentences
    Summary · context
    A single blind, randomized, placebo-controlled trial of 5 months duration was conducted.
    Summary · context
    Ten women and 9 men between the ages of 55-71 yr self-injected placebo (saline) s.c. nightly for 4 weeks followed by 16 weeks of [Nle27]GHRH-(1-29)-NH2 at a dose of 10 microg/kg.
  16. 16HumanRandomized controlled trialActivity measurement

    In age-advanced women, the GHRH analog significantly increased 12-h integrated nocturnal GH levels compared with placebo.

    In plain wordsIn older women, the GHRH analog raised overnight growth hormone levels more than placebo.

    Peptide
    Sermorelin
    Outcome
    Increase12-h integrated nocturnal GH in women
    Study

    n = 10

    Comparator
    Placebo
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    10 microg/kg · subcutaneous · 16 weeksAs given in this study (human).

    Source sentences

    Summary
    Compared with placebo, GHRH analog induced a significant increase in 12-h integrated nocturnal GH levels in women (P < 0.01) and men (P < 0.05).
    2 context sentences
    Summary · context
    A single blind, randomized, placebo-controlled trial of 5 months duration was conducted.
    Summary · context
    Ten women and 9 men between the ages of 55-71 yr self-injected placebo (saline) s.c. nightly for 4 weeks followed by 16 weeks of [Nle27]GHRH-(1-29)-NH2 at a dose of 10 microg/kg.
  17. 17HumanRandomized controlled trialActivity measurement

    In age-advanced women, GHBP concentrations increased significantly within 4 weeks of GHRH analog treatment.

    In plain wordsIn older women, the GHRH analog raised blood growth-hormone-binding protein within 4 weeks.

    Peptide
    Sermorelin
    Outcome
    IncreaseGH-binding protein in women
    Study

    n = 10

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    10 microg/kg · subcutaneous · 16 weeksAs given in this study (human).

    Source sentences

    Summary
    Within 4 weeks, GHBP concentrations were significantly increased (P < 0.01) in women, but not in men.
    2 context sentences
    Summary · context
    A single blind, randomized, placebo-controlled trial of 5 months duration was conducted.
    Summary · context
    Ten women and 9 men between the ages of 55-71 yr self-injected placebo (saline) s.c. nightly for 4 weeks followed by 16 weeks of [Nle27]GHRH-(1-29)-NH2 at a dose of 10 microg/kg.
  18. 18HumanRandomized controlled trialEfficacy outcome

    In age-advanced women, GHRH analog treatment did not significantly change insulin sensitivity.

    In plain wordsIn older women, the GHRH analog did not change insulin sensitivity.

    Peptide
    Sermorelin
    Outcome
    No significant changeInsulin sensitivity in women
    Study

    n = 10

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    10 microg/kg · subcutaneous · 16 weeksAs given in this study (human).

    Source sentences

    Summary
    a significant increase in insulin sensitivity occurred in men (P < 0.05), but not in women.
    2 context sentences
    Summary · context
    A single blind, randomized, placebo-controlled trial of 5 months duration was conducted.
    Summary · context
    Ten women and 9 men between the ages of 55-71 yr self-injected placebo (saline) s.c. nightly for 4 weeks followed by 16 weeks of [Nle27]GHRH-(1-29)-NH2 at a dose of 10 microg/kg.
  19. 19HumanRandomized controlled trialEfficacy outcome

    In age-advanced women, GHRH analog treatment did not significantly improve general well-being.

    In plain wordsIn older women, the GHRH analog did not improve how well they felt in general.

    Peptide
    Sermorelin
    Outcome
    No significant changeGeneral well-being in women
    Study

    n = 10

    Outcome group
    Quality of life · Whole body
    Studied dose
    10 microg/kg · subcutaneous · 16 weeksAs given in this study (human).

    Source sentences

    Summary
    Assessment of quality of life parameters revealed a significant improvement in general well-being (P < 0.05) and libido (P < 0.01) in men, but not in women
    2 context sentences
    Summary · context
    A single blind, randomized, placebo-controlled trial of 5 months duration was conducted.
    Summary · context
    Ten women and 9 men between the ages of 55-71 yr self-injected placebo (saline) s.c. nightly for 4 weeks followed by 16 weeks of [Nle27]GHRH-(1-29)-NH2 at a dose of 10 microg/kg.
  20. 20HumanRandomized controlled trialEfficacy outcome

    In age-advanced women, GHRH analog treatment did not significantly improve libido.

    In plain wordsIn older women, the GHRH analog did not improve sex drive.

    Peptide
    Sermorelin
    Outcome
    No significant changeLibido in women
    Study

    n = 10

    Outcome group
    Sexual function · Reproductive and sexual health
    Studied dose
    10 microg/kg · subcutaneous · 16 weeksAs given in this study (human).

    Source sentences

    Summary
    Assessment of quality of life parameters revealed a significant improvement in general well-being (P < 0.05) and libido (P < 0.01) in men, but not in women
    2 context sentences
    Summary · context
    A single blind, randomized, placebo-controlled trial of 5 months duration was conducted.
    Summary · context
    Ten women and 9 men between the ages of 55-71 yr self-injected placebo (saline) s.c. nightly for 4 weeks followed by 16 weeks of [Nle27]GHRH-(1-29)-NH2 at a dose of 10 microg/kg.
  21. 21HumanRandomized controlled trialActivity measurement

    In age-advanced men, the GHRH analog significantly increased 12-h integrated nocturnal GH levels compared with placebo.

    In plain wordsIn older men, the GHRH analog raised overnight growth hormone levels more than placebo.

    Peptide
    Sermorelin
    Outcome
    Increase12-h integrated nocturnal GH in men
    Study

    n = 9

    Comparator
    Placebo
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    10 microg/kg · subcutaneous · 16 weeksAs given in this study (human).

    Source sentences

    Summary
    Compared with placebo, GHRH analog induced a significant increase in 12-h integrated nocturnal GH levels in women (P < 0.01) and men (P < 0.05).
    2 context sentences
    Summary · context
    A single blind, randomized, placebo-controlled trial of 5 months duration was conducted.
    Summary · context
    Ten women and 9 men between the ages of 55-71 yr self-injected placebo (saline) s.c. nightly for 4 weeks followed by 16 weeks of [Nle27]GHRH-(1-29)-NH2 at a dose of 10 microg/kg.
  22. 22HumanRandomized controlled trialActivity measurement

    In age-advanced men, GHBP concentrations did not increase significantly with GHRH analog treatment.

    In plain wordsIn older men, the GHRH analog did not raise blood growth-hormone-binding protein.

    Peptide
    Sermorelin
    Outcome
    No significant changeGH-binding protein in men
    Study

    n = 9

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    10 microg/kg · subcutaneous · 16 weeksAs given in this study (human).

    Source sentences

    Summary
    Within 4 weeks, GHBP concentrations were significantly increased (P < 0.01) in women, but not in men.
    2 context sentences
    Summary · context
    A single blind, randomized, placebo-controlled trial of 5 months duration was conducted.
    Summary · context
    Ten women and 9 men between the ages of 55-71 yr self-injected placebo (saline) s.c. nightly for 4 weeks followed by 16 weeks of [Nle27]GHRH-(1-29)-NH2 at a dose of 10 microg/kg.
  23. 23HumanRandomized controlled trialEfficacy outcome

    In age-advanced men, GHRH analog treatment significantly increased lean body mass; the increase was in men only.

    In plain wordsIn older men, the GHRH analog increased lean body mass. This was seen in men only.

    Peptide
    Sermorelin
    Outcome
    IncreaseLean body mass in men
    Study

    n = 9

    Outcome group
    Body composition · Metabolic and weight
    Studied dose
    10 microg/kg · subcutaneous · 16 weeksAs given in this study (human).

    Source sentences

    Summary
    increased lean body mass in men only (P < 0.05)
    2 context sentences
    Summary · context
    A single blind, randomized, placebo-controlled trial of 5 months duration was conducted.
    Summary · context
    Ten women and 9 men between the ages of 55-71 yr self-injected placebo (saline) s.c. nightly for 4 weeks followed by 16 weeks of [Nle27]GHRH-(1-29)-NH2 at a dose of 10 microg/kg.
  24. 24HumanRandomized controlled trialEfficacy outcome

    In age-advanced men, GHRH analog treatment significantly increased insulin sensitivity.

    In plain wordsIn older men, the GHRH analog improved insulin sensitivity.

    Peptide
    Sermorelin
    Outcome
    IncreaseInsulin sensitivity in men
    Study

    n = 9

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    10 microg/kg · subcutaneous · 16 weeksAs given in this study (human).

    Source sentences

    Summary
    a significant increase in insulin sensitivity occurred in men (P < 0.05), but not in women.
    2 context sentences
    Summary · context
    A single blind, randomized, placebo-controlled trial of 5 months duration was conducted.
    Summary · context
    Ten women and 9 men between the ages of 55-71 yr self-injected placebo (saline) s.c. nightly for 4 weeks followed by 16 weeks of [Nle27]GHRH-(1-29)-NH2 at a dose of 10 microg/kg.
  25. 25HumanRandomized controlled trialEfficacy outcome

    In age-advanced men, GHRH analog treatment significantly improved general well-being.

    In plain wordsIn older men, the GHRH analog improved how well they felt in general.

    Peptide
    Sermorelin
    Outcome
    IncreaseGeneral well-being in men
    Study

    n = 9

    Outcome group
    Quality of life · Whole body
    Studied dose
    10 microg/kg · subcutaneous · 16 weeksAs given in this study (human).

    Source sentences

    Summary
    Assessment of quality of life parameters revealed a significant improvement in general well-being (P < 0.05) and libido (P < 0.01) in men, but not in women
    2 context sentences
    Summary · context
    A single blind, randomized, placebo-controlled trial of 5 months duration was conducted.
    Summary · context
    Ten women and 9 men between the ages of 55-71 yr self-injected placebo (saline) s.c. nightly for 4 weeks followed by 16 weeks of [Nle27]GHRH-(1-29)-NH2 at a dose of 10 microg/kg.
  26. 26HumanRandomized controlled trialEfficacy outcome

    In age-advanced men, GHRH analog treatment significantly improved libido.

    In plain wordsIn older men, the GHRH analog improved sex drive.

    Peptide
    Sermorelin
    Outcome
    IncreaseLibido in men
    Study

    n = 9

    Outcome group
    Sexual function · Reproductive and sexual health
    Studied dose
    10 microg/kg · subcutaneous · 16 weeksAs given in this study (human).

    Source sentences

    Summary
    Assessment of quality of life parameters revealed a significant improvement in general well-being (P < 0.05) and libido (P < 0.01) in men, but not in women
    2 context sentences
    Summary · context
    A single blind, randomized, placebo-controlled trial of 5 months duration was conducted.
    Summary · context
    Ten women and 9 men between the ages of 55-71 yr self-injected placebo (saline) s.c. nightly for 4 weeks followed by 16 weeks of [Nle27]GHRH-(1-29)-NH2 at a dose of 10 microg/kg.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 19:08 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.